EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Efficacy analysis of icaritin combined with transarterial chemoembolization in hepatocellular carcinoma stratified by different child-pugh classes

Jingxuan Xu, Yao Xing, Fenhua Zhao, Bufu Tang, Xinghai Li, Jiangping Cun, Huilin Lu, Xiangwen Xia, Hongjie Fan, Yuting Gu, Tao Xu

Frontiers in Immunology · 30.07.2026 · 17

DOI: 10.3389/fimmu.2026.1876151 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Frontiers in Immunology, online erschienen am 30.07.2026. Verfasst von Jingxuan Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Dongyang Hospital Affiliated to Wenzhou Medical University, Dongyang, Zhejiang, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Flavonoids. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate if transarterial chemoembolization (TACE) combined with Icaritin provides additional survival benefits compared to TACE alone in intermediate-to-advanced hepatocellular carcinoma (HCC) across different Child-Pugh classes.

Background

TACE is a standard locoregional therapy for intermediate-to-advanced HCC, yet monotherapy yields limited long-term survival. Icaritin, an immunomodulator, demonstrates survival benefits in advanced HCC with a favorable safety profile lacking severe hepatotoxicity or bone marrow suppression.

Methods

This multicenter retrospective cohort study included patients with Barcelona Clinic Liver Cancer (BCLC) stage B and C HCC. Propensity score matching (PSM) was utilized to balance baseline covariates between the TACE with Icaritin and TACE alone groups. The primary endpoint was overall survival (OS).

Results

Following PSM, 250 patients were evaluated. In the Child-Pugh grade A group, TACE combined with Icaritin was associated with longer median OS than TACE alone (28.8 vs. 15.7 months; HR, 0.42; 95% CI, 0.29-0.62; P<0.001). Median PFS was also longer in the combination group (9.7 vs. 8.1 months; HR, 0.66; 95% CI, 0.49-0.90; P = 0.007). In Child-Pugh subgroup analyses, the treatment effect was most consistent in patients with Child-Pugh grade A liver function. In Child-Pugh grade B patients, OS favored the combination therapy, whereas the PFS result was not statistically definitive. ORR (49.6% vs. 47.2%) and DCR (83.2% vs. 74.4%) were comparable. The combination regimen did not significantly increase grade 3–4 liver function-related adverse events.

Conclusions

TACE combined with Icaritin was associated with improved survival outcomes, with the most consistent benefit observed in patients with Child-Pugh grade A liver function. In Child-Pugh grade B patients, the findings should be interpreted cautiously because of the limited subgroup size and insufficient statistical power.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticFlavonoidsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedTreatment OutcomeCombined Modality TherapyNeoplasm Staging

Stichwörter der Autor:innen

hepatocellular carcinomaicaritinimmunomodulatoroverall survivaltransarterial chemoembolization

Substanzen

icaritinFlavonoids

Autor:innen und Institutionen

  • Department of Radiology, Dongyang Hospital Affiliated to Wenzhou Medical University, Dongyang, Zhejiang, China.
  • School of Clinical Medicine, North Sichuan Medical College, Nanchong, Sichuan, China.
  • Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Minimally Invasive Intervention, Ganzhou People's Hospital, Ganzhou, China.
  • Department of Radiology, the Second Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Department of Interventional Therapy, Xinxiang Central Hospital/the Fourth Clinical College of Xinxiang Medical University, Xinxiang, Henan, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xu, J., Xing, Y., Zhao, F., Tang, B., Li, X., Cun, J., Lu, H., Xia, X., Fan, H., Gu, Y., & Xu, T. (2026). Efficacy analysis of icaritin combined with transarterial chemoembolization in hepatocellular carcinoma stratified by different child-pugh classes. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1876151

Vancouver

Xu J, Xing Y, Zhao F, Tang B, Li X, Cun J, et al. Efficacy analysis of icaritin combined with transarterial chemoembolization in hepatocellular carcinoma stratified by different child-pugh classes. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1876151

BibTeX
@article{Xu2026,
  author = {Xu, Jingxuan and Xing, Yao and Zhao, Fenhua and Tang, Bufu and Li, Xinghai and Cun, Jiangping and Lu, Huilin and Xia, Xiangwen and Fan, Hongjie and Gu, Yuting and Xu, Tao},
  title = {Efficacy analysis of icaritin combined with transarterial chemoembolization in hepatocellular carcinoma stratified by different child-pugh classes},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1876151}
}
Kostenlos starten →